Clay LaTonya A, Straub Kurtis W, Adrianos Sherry L, Daniels Jonathan, Blackwell Jerry L, Bryant Lonnie T, McClee Von, Green Judith A, Edwin Samuel S
Centers for Disease Control and Prevention, Center for Preparedness and Response, Division of Select Agents and Toxins, Atlanta, Georgia, USA.
Appl Biosaf. 2022 Jun 1;27(2):84-91. doi: 10.1089/apb.2021.0039. Epub 2022 May 27.
is a Tier 1 overlap select agent and subject to the select agent regulations (42 CFR §73 and 9 CFR §121). It is a gram-negative, motile, soil saprophyte, and the etiologic agent of melioidosis. infection can produce systemic illness and can be fatal in the absence of appropriate treatment. Laboratory exposures involving this organism may occur when appropriate containment measures are not employed. Current disease treatment inadequacies and the risk factors associated with melioidosis make this an agent of primary concern in research, commercial, and clinical laboratory environments.
This study presents data reported to Centers for Disease Control and Prevention (CDC), Division of Select Agents and Toxins for releases involving in 2017-2019 that occurred in Biosafety Level (BSL)-2 and BSL-3 laboratories. Fifty-one Animal and Plant Health Inspection Service (APHIS)/CDC Form 3 release reports led to the medical surveillance of 275 individuals. Entities offered post-exposure prophylaxis to ∼76% of the individuals impacted in the presented events.
Laboratory safety can be improved by implementing appropriate safety precautions to minimize exposures. Most of the incidents discussed in this evidence-based report occurred during work conducted in the absence of primary containment. None of the releases resulted in illness, death, or transmission to or among workers, nor was there transmission outside of a laboratory into the surrounding environment or community. Effective risk assessment and management strategies coupled with standard and special microbiological policies and procedures can result in reduced exposures and improved safety at facilities.
是一级重叠选择剂,受选择剂法规(42 CFR§73和9 CFR§121)约束。它是一种革兰氏阴性、有运动性的土壤腐生菌,是类鼻疽的病原体。感染可导致全身性疾病,若未进行适当治疗可能致命。当未采取适当的防护措施时,可能会发生涉及这种微生物的实验室暴露。目前疾病治疗的不足以及与类鼻疽相关的风险因素,使其成为研究、商业和临床实验室环境中主要关注的病原体。
本研究展示了2017 - 2019年期间向疾病控制与预防中心(CDC)选择剂与毒素司报告的、发生在生物安全2级(BSL - 2)和生物安全3级(BSL - 3)实验室的涉及的释放事件数据。51份动植物卫生检验局(APHIS)/CDC表3释放报告导致对275人进行医学监测。在本报告所述事件中,相关机构对约76%受影响个体提供了暴露后预防措施。
通过实施适当的安全预防措施以尽量减少暴露,可提高实验室安全性。这份基于证据的报告中讨论的大多数事件发生在没有一级防护的工作过程中。所有释放事件均未导致疾病、死亡或在工作人员之间传播,也未从实验室传播到周围环境或社区。有效的风险评估和管理策略,再加上标准和特殊的微生物学政策及程序,可减少暴露并提高设施安全性。